Experienced in Ocular Hypertension (OHT)

Dr. Sashi K. Makam

Internal Medicine
Horizon Medical Group PC
21 Edward J Lempka Dr, Family Practice, 
Florida, NY 
Offers Telehealth
Experienced in Ocular Hypertension (OHT)
Horizon Medical Group PC
21 Edward J Lempka Dr, Family Practice, 
Florida, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sashi Makam is a primary care provider, practicing in Internal Medicine in Florida, New York. Dr. Makam is rated as an Experienced provider by MediFind in the treatment of Ocular Hypertension (OHT). His top areas of expertise are Hypothyroidism, Obesity in Children, High Cholesterol, and Familial Hypertriglyceridemia.

His clinical research consists of participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in NY
Hospital Affiliations
Vassar Brothers Medical Center
St Luke's Cornwall Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
Nippon Life
  • INSURANCE PLAN
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

HORIZON MEDICAL GROUP PC
21 Edward J Lempka Dr, Family Practice, Florida, NY 10921
Other Locations
HORIZON MEDICAL GROUP PC
1460 State Route 17m, Suite A, Chester, NY 10918
HORIZON MEDICAL GROUP PC
277 Quassaick Ave, New Windsor, NY 12553

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2025
Intervention Type: Drug
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Mixed Dyslipidemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Mixed Dyslipidemia
Enrollment Status: Completed
Publish Date: October 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Biological
Study Drug: Depemokimab
Study Phase: Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Other
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening BLUE-C
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening BLUE-C
Enrollment Status: Completed
Publish Date: September 01, 2023
Intervention Type: Procedure, Diagnostic test
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy
A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy
Enrollment Status: Completed
Publish Date: June 25, 2020
Intervention Type: Drug
Study Phase: Phase 2
Lyme Test Indication Combinations (LyTIC) Study
Lyme Test Indication Combinations (LyTIC) Study
Enrollment Status: Terminated
Publish Date: December 13, 2018
Intervention Type: Diagnostic test
A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme Disease
A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme Disease
Enrollment Status: Terminated
Publish Date: January 17, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 13 Less Clinical Trials
Similar Doctors
Distinguished in Ocular Hypertension (OHT)
Dr. Fei Yu
Internal Medicine
Distinguished in Ocular Hypertension (OHT)
Dr. Fei Yu
Internal Medicine

HMH - Primary Care - Fort Lee

301 Bridge Plaza North, Suite 300, 
Fort Lee, NJ 
 (39.4 miles away)
848-308-4690
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Fei Yu is a primary care provider, practicing in Internal Medicine in Fort Lee, New Jersey. Dr. Yu is rated as an Advanced provider by MediFind in the treatment of Ocular Hypertension (OHT). Her top areas of expertise are Ocular Hypertension (OHT), Gingivostomatitis, Diabetic Retinopathy, Trabeculectomy, and Cataract Removal.

Advanced in Ocular Hypertension (OHT)
Dr. Berhane Wubshet
Internal Medicine
Advanced in Ocular Hypertension (OHT)
Dr. Berhane Wubshet
Internal Medicine

Kingsbrook Medical Associates PC

585 Schenectady Ave, 
Brooklyn, NY 
 (52.0 miles away)
718-604-5000
Languages Spoken:
English
See accepted insurances

Berhane Wubshet is a primary care provider, practicing in Internal Medicine in Brooklyn, New York. Dr. Wubshet is rated as an Advanced provider by MediFind in the treatment of Ocular Hypertension (OHT). His top areas of expertise are Ocular Hypertension (OHT), Anemia, Anal Cancer, and Presbyopia.

Advanced in Ocular Hypertension (OHT)
Dr. Min K. Song
Internal Medicine
Advanced in Ocular Hypertension (OHT)
Dr. Min K. Song
Internal Medicine

Sandg Medical Office, PC

2 Allen St, 3c, 
New York, NY 
 (47.3 miles away)
212-233-2078
Languages Spoken:
English
See accepted insurances

Min Song is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Song is rated as an Advanced provider by MediFind in the treatment of Ocular Hypertension (OHT). Her top areas of expertise are Viral Gastroenteritis, Colitis, Ocular Hypertension (OHT), and Sutton Disease 2.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Makam's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 189 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile